Jubilant Pharmova Q2 Results 2025 Highlights: Net Profit Rises by 17.02% & Revenue Up 12.2% YoY

Click and Sign Up to Get Live Updates on Q2 Results 

Jubilant Pharmova Q2 Results FY26: During Q2 FY26, Jubilant Pharmova’s profit increased 17.02% YoY, while revenue increased by 12.22% YoY. The company posted robust numbers, with Q2 PAT at ₹120.30 crores and revenue at ₹1,966.40 crores. Jubilant Pharmova showed its Q2 results on 31st October 2025.  

Jubilant Pharmova Q2 Results FY26: Extracts of FY25 & FY26

Jubilant Pharmova Q2 Results FY26 Highlights (Q2 FY26 vs FY25)

• Jubilant Pharmova clocked Q2 FY26 consolidated revenue of ₹1,966.40 crores vs ₹1,752.30 crores. 
• On the profit front, Jubilant Pharmova earned a consolidated PAT of ₹120.30 crore in Q2 FY26. During FY25, the company’s PAT stood at ₹102.80 crore.
• According to the consolidated figures, Jubilant Pharmova’s quarterly PAT increased by 17.02% YoY, while revenue increased by 12.22%.
• Jubilant Pharmova clocked Q2 FY26 standalone revenue of ₹66.40 crores vs ₹61.40 crores. 
• On the profit front, Jubilant Pharmova earned a standalone PAT of -₹48.00 crore in Q2 FY26. During FY25, the company’s PAT stood at ₹14.30 crore.
• According to the standalone figures, Jubilant Pharmova’s quarterly PAT decreased by 435.66% YoY, while revenue increased by 8.14%.

Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!

About Jubilant Pharmova Limited

Jubilant Pharmova is a global integrated pharmaceutical company with three primary business segments: contract Research and development services, Pharmaceuticals, and Proprietary Novel Drugs. The Pharmaceuticals segment includes radiopharmaceuticals, allergy immunotherapy, and contract manufacturing of sterile injectables and generic formulations. The company has a significant presence in the US, operating the second-largest radiopharmacy network with 46 locations, and manufacturing facilities in India, the US, and Canada, which are approved by the US FDA.  

Jubilant Pharmova Share Price Performance

On the opening bell on 3rd November 2025, Jubilant Pharmova shares opened at ₹1,109.80 per share. However, the initial gains have since eroded, and Jubilant Pharmova shares are trading at ₹1,141.60 per share, higher than the opening price.    

Considering the long-term achievements, Jubilant Pharmova shares have yielded returns of approximately 25.73% over the past 6 months, and 1-year returns stand at -8.85%. Over the maximum timeframe, Jubilant Pharmova shares delivered a 27.71% return to investors. 

What Analysts Expect Post Q2 Results?

Following Jubilant Pharmova’s robust Q2 results, analysts expect its share price to rise. According to analysts, Jubilant Pharmova’s share price could reach ₹1,235.30 per share in the coming year and, in a downturn, could fall to ₹ 1,120.60 per share. However, one must ignore stock market volatility and invest in Jubilant Pharmova’s shares after thorough research. 

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.

Recent Articles

Nestle Q2 Results FY26: Q2 PAT Falls 17.38% to ₹743.17 Crore; Revenue Up 10.57% YoY

Inspira Enterprise India IPO Details: Everything You Should Know about 

Swaraj Engines Q2 Results FY26: Q2 PAT Rises 8.88% to ₹49 Crore; Revenue Up 8.62% YoY

HDB Financial Q2 Results FY26: Q2 PAT Falls 1.5% to ₹581 Crore; Revenue Up 13.42% YoY

BEL Gears Up for Q2 Reveal on 4th November; Check Key Expectations Here

Paytm Gears Up for Q2 Reveal on 4th November; Check Key Expectations Here

Blue Dart Gears Up for Q2 Reveal on 28th October; Check Key Expectations Here